RJR1 Stock Chart & Stats
€1.18
-€0.09(-6.90%)
At close: 4:00 PM EDT
€1.18
-€0.09(-6.90%)
Day’s Range― - ―
52-Week Range€0.97 - €2.86
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
€99.19M
Enterprise Value€171.97M
Total Cash (Recent Filing)€10.49M
Total Debt (Recent Filing)€5.17M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding100,202,180
10 Day Avg. Volume0
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.68Price Target Upside126.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€30.31M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue GrowthRapid growth in robotic catheter revenue is strengthening the recurring portion of Stereotaxis’s business model. Rising procedure-linked revenue can improve visibility, deepen customer utilization, and create a more durable foundation than relying primarily on intermittent capital-equipment installations.
Gross Margin Expansion PotentialThe recurring business already carries stronger margins than system sales, and management expects further expansion as volumes increase. If achieved, this mix shift could improve operating leverage, support reinvestment, and make the stated path to cash-flow profitability more achievable.
Expanding Robotic PlatformA broader cleared product portfolio expands Stereotaxis’s role across robotic procedures and provides additional avenues for hospital adoption. The Robocath acquisition and more than 150,000 patients treated at over 100 hospitals also reinforce platform credibility and commercial reach.
Bears Say
Persistent Losses And Cash BurnStereotaxis has not yet demonstrated self-funding operations, with recurring losses translating into substantial operating and free-cash-flow outflows. Continued burn can constrain investment flexibility and increase dependence on financing before the company reaches targeted cash-flow profitability.
Catheter Supply ConstraintsSupply constraints are preventing the company from fully converting strong customer demand into near-term revenue. A prolonged manufacturing ramp or backlog could delay recurring-revenue growth, slow clinical adoption, and postpone the operating leverage expected from higher catheter volumes.
Weak System Sales And MarginsThe decline in system revenue highlights continued dependence on uneven hospital installation timing, while low system margins reduce the contribution from capital sales. Until installations recover and volumes improve, the business may remain exposed to volatile revenue and limited operating leverage.
Stereotaxis News
RJR1 FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was €0.96 and its highest was €2.86 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is €99.19M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Aug 11, 2026. The company reported -€0.045 earnings per share for the quarter.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 100,202,180 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -€0.045 in its last earnings report. Following the earnings report the stock price went up 1.233%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in DE:RJR1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€2.68 (126.91% Upside)
€2.68 (126.91% Upside)
Blogger Sentiment
Neutral
DE:RJR1 Sentiment 67%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.06%
12-Months-Change
Fundamentals
Return on Equity
-132.62%
Trailing 12-Months
Asset Growth
35.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
RJR1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple material positive operational and commercial milestones (FDA clearances, product launches, strong sequential and year‑over‑year growth in robotically navigated catheter revenue, Synchrony early sales, GenesisX installs and OEM compatibility progress, strategic Robocath acquisition) that point to an improving growth trajectory and a clear path to higher recurring revenue and margin expansion. Offsetting these positives are near‑term execution challenges: supply constraints for MAGiC catheters limiting sales, a YoY decline in system revenue driven by a missed system delivery, depressed system margins due to low volumes, ongoing operating losses and negative free cash flow, and transition‑related procedure pressure. Management provided concrete guidance and reiterated a plan to reach cash‑flow profitability in H1 2027, relying on manufacturing ramp and modest capital sales. Overall, the call indicates constructive commercial inflection and credible progress toward profitability, but with meaningful near‑term operational and financial risks that must be managed.View all DE:RJR1 earnings summariesRJR1 Stock 12 Month Forecast
Average Price Target
€2.68
▲(126.91% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―